Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Editorial: Therapeutic Modulation of the Complement System: Clinical Indications and Emerging Drug Leads.

Mastellos DC, Reis ES, Lambris JD.

Front Immunol. 2020 Jan 9;10:3029. doi: 10.3389/fimmu.2019.03029. eCollection 2019. No abstract available.

2.

Fear or Humour in anti-smoking campaigns? Impact on perceived effectiveness and support for tobacco control Policies.

Reis ES, Arriaga PPLE, Postolache OA.

Cien Saude Colet. 2019 Dec;24(12):4727-4738. doi: 10.1590/1413-812320182412.09322018. Epub 2018 May 23.

3.

Complement C3 inhibition by compstatin Cp40 prevents intra- and extravascular hemolysis of red blood cells.

Baas I, Delvasto-Nuñez L, Ligthart P, Brouwer C, Folman C, Reis ES, Ricklin D, Lambris JD, Wouters D, de Haas M, Jongerius I, Zeerleder SS.

Haematologica. 2020 Jan 31;105(2):e57-e60. doi: 10.3324/haematol.2019.216028. Print 2020. No abstract available.

4.

Prevalence of Carotid Stenosis and Incidence of Ischemic Stroke in Patients Undergoing Non-Coronary Cardiac Surgery.

Costa MACD, Nadal JP, Okamoto JM, Betero AL, Schafranski MD, Gomes RZ, Reis ESDS.

Braz J Cardiovasc Surg. 2019 Dec 1;34(5):550-559. doi: 10.21470/1678-9741-2018-0127.

5.

New insights into the immune functions of complement.

Reis ES, Mastellos DC, Hajishengallis G, Lambris JD.

Nat Rev Immunol. 2019 Aug;19(8):503-516. doi: 10.1038/s41577-019-0168-x. Review.

PMID:
31048789
6.

Complement-Dependent Mechanisms and Interventions in Periodontal Disease.

Hajishengallis G, Kajikawa T, Hajishengallis E, Maekawa T, Reis ES, Mastellos DC, Yancopoulou D, Hasturk H, Lambris JD.

Front Immunol. 2019 Mar 12;10:406. doi: 10.3389/fimmu.2019.00406. eCollection 2019. Review.

7.

Taming hemodialysis-induced inflammation: Are complement C3 inhibitors a viable option?

Mastellos DC, Reis ES, Biglarnia AR, Waldman M, Quigg RJ, Huber-Lang M, Seelen MA, Daha MR, Lambris JD.

Clin Immunol. 2019 Jan;198:102-105. doi: 10.1016/j.clim.2018.11.010. Epub 2018 Nov 22.

PMID:
30472267
8.

Complement C5a-Mediated TAM-ing of Antitumor Immunity Drives Squamous Carcinogenesis.

Mastellos DC, Reis ES, Lambris JD.

Cancer Cell. 2018 Oct 8;34(4):531-533. doi: 10.1016/j.ccell.2018.09.005.

9.

Safety profile after prolonged C3 inhibition.

Reis ES, Berger N, Wang X, Koutsogiannaki S, Doot RK, Gumas JT, Foukas PG, Resuello RRG, Tuplano JV, Kukis D, Tarantal AF, Young AJ, Kajikawa T, Soulika AM, Mastellos DC, Yancopoulou D, Biglarnia AR, Huber-Lang M, Hajishengallis G, Nilsson B, Lambris JD.

Clin Immunol. 2018 Dec;197:96-106. doi: 10.1016/j.clim.2018.09.004. Epub 2018 Oct 10.

10.

Gingival Exudatome Dynamics Implicate Inhibition of the Alternative Complement Pathway in the Protective Action of the C3 Inhibitor Cp40 in Nonhuman Primate Periodontitis.

Bostanci N, Bao K, Li X, Maekawa T, Grossmann J, Panse C, Briones RA, Resuello RRG, Tuplano JV, Garcia CAG, Reis ES, Lambris JD, Hajishengallis G.

J Proteome Res. 2018 Sep 7;17(9):3153-3175. doi: 10.1021/acs.jproteome.8b00263. Epub 2018 Aug 29.

11.

Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria.

Mastellos DC, Reis ES, Yancopoulou D, Risitano AM, Lambris JD.

Semin Hematol. 2018 Jul;55(3):167-175. doi: 10.1053/j.seminhematol.2018.02.002. Epub 2018 Feb 14. Review.

12.

Novel Immunoassay for Complement Activation by PF4/Heparin Complexes.

Khandelwal S, Johnson AM, Liu J, Keire D, Sommers C, Ravi J, Lee GM, Lambris JD, Reis ES, Arepally GM.

Thromb Haemost. 2018 Aug;118(8):1484-1487. doi: 10.1055/s-0038-1660858. Epub 2018 Jun 30. No abstract available.

13.

New Analogs of the Complement C3 Inhibitor Compstatin with Increased Solubility and Improved Pharmacokinetic Profile.

Berger N, Alayi TD, Resuello RRG, Tuplano JV, Reis ES, Lambris JD.

J Med Chem. 2018 Jul 26;61(14):6153-6162. doi: 10.1021/acs.jmedchem.8b00560. Epub 2018 Jul 3.

PMID:
29920096
14.

Functional Relevance of the Anaphylatoxin Receptor C3aR for Platelet Function and Arterial Thrombus Formation Marks an Intersection Point Between Innate Immunity and Thrombosis.

Sauter RJ, Sauter M, Reis ES, Emschermann FN, Nording H, Ebenhöch S, Kraft P, Münzer P, Mauler M, Rheinlaender J, Madlung J, Edlich F, Schäffer TE, Meuth SG, Duerschmied D, Geisler T, Borst O, Gawaz M, Kleinschnitz C, Lambris JD, Langer HF.

Circulation. 2018 Oct 16;138(16):1720-1735. doi: 10.1161/CIRCULATIONAHA.118.034600. Erratum in: Circulation. 2019 Jan 15;139(3):e8. Dürschmied, Daniel [corrected to Duerschmied, Daniel].

15.

The renaissance of complement therapeutics.

Ricklin D, Mastellos DC, Reis ES, Lambris JD.

Nat Rev Nephrol. 2018 Jan;14(1):26-47. doi: 10.1038/nrneph.2017.156. Epub 2017 Dec 4. Review.

16.

Novel mechanisms and functions of complement.

Hajishengallis G, Reis ES, Mastellos DC, Ricklin D, Lambris JD.

Nat Immunol. 2017 Nov 16;18(12):1288-1298. doi: 10.1038/ni.3858. Review.

17.

Local endothelial complement activation reverses endothelial quiescence, enabling t-cell homing, and tumor control during t-cell immunotherapy.

Facciabene A, De Sanctis F, Pierini S, Reis ES, Balint K, Facciponte J, Rueter J, Kagabu M, Magotti P, Lanitis E, DeAngelis RA, Buckanovich RJ, Song WC, Lambris JD, Coukos G.

Oncoimmunology. 2017 Jun 8;6(9):e1326442. doi: 10.1080/2162402X.2017.1326442. eCollection 2017.

18.

Complement in cancer: untangling an intricate relationship.

Reis ES, Mastellos DC, Ricklin D, Mantovani A, Lambris JD.

Nat Rev Immunol. 2018 Jan;18(1):5-18. doi: 10.1038/nri.2017.97. Epub 2017 Sep 18. Review.

19.

Safety and Efficacy of the Complement Inhibitor AMY-101 in a Natural Model of Periodontitis in Non-human Primates.

Kajikawa T, Briones RA, Resuello RRG, Tuplano JV, Reis ES, Hajishengallis E, Garcia CAG, Yancopoulou D, Lambris JD, Hajishengallis G.

Mol Ther Methods Clin Dev. 2017 Aug 18;6:207-215. doi: 10.1016/j.omtm.2017.08.001. eCollection 2017 Sep 15.

20.

Complement component C3aR constitutes a novel regulator for chick eye morphogenesis.

Grajales-Esquivel E, Luz-Madrigal A, Bierly J, Haynes T, Reis ES, Han Z, Gutierrez C, McKinney Z, Tzekou A, Lambris JD, Tsonis PA, Del Rio-Tsonis K.

Dev Biol. 2017 Aug 1;428(1):88-100. doi: 10.1016/j.ydbio.2017.05.019. Epub 2017 May 30.

21.

Complement C3-Targeted Therapy: Replacing Long-Held Assertions with Evidence-Based Discovery.

Mastellos DC, Reis ES, Ricklin D, Smith RJ, Lambris JD.

Trends Immunol. 2017 Jun;38(6):383-394. doi: 10.1016/j.it.2017.03.003. Epub 2017 Apr 14.

22.

Pericytes and immune cells contribute to complement activation in tubulointerstitial fibrosis.

Xavier S, Sahu RK, Landes SG, Yu J, Taylor RP, Ayyadevara S, Megyesi J, Stallcup WB, Duffield JS, Reis ES, Lambris JD, Portilla D.

Am J Physiol Renal Physiol. 2017 Mar 1;312(3):F516-F532. doi: 10.1152/ajprenal.00604.2016. Epub 2017 Jan 4.

23.

Method development and validation for the quantitation of the complement inhibitor Cp40 in human and cynomolgus monkey plasma by UPLC-ESI-MS.

Primikyri A, Papanastasiou M, Sarigiannis Y, Koutsogiannaki S, Reis ES, Tuplano JV, Resuello RR, Nilsson B, Ricklin D, Lambris JD.

J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Jan 15;1041-1042:19-26. doi: 10.1016/j.jchromb.2016.12.004. Epub 2016 Dec 6.

24.

Complement component C3 - The "Swiss Army Knife" of innate immunity and host defense.

Ricklin D, Reis ES, Mastellos DC, Gros P, Lambris JD.

Immunol Rev. 2016 Nov;274(1):33-58. doi: 10.1111/imr.12500. Review.

25.

Anticoagulation Quality and Complications of using Vitamin K Antagonists in the Cardiac Surgery Outpatient Clinic.

da Costa MAC, Krum LK, Geraldino JD, Schafranski MD, Gomes RZ, Reis ES.

Braz J Cardiovasc Surg. 2016 May-Jun;31(3):239-245. doi: 10.5935/1678-9741.20160055.

26.

Compstatin Cp40 blocks hematin-mediated deposition of C3b fragments on erythrocytes: Implications for treatment of malarial anemia.

Lindorfer MA, Cook EM, Reis ES, Ricklin D, Risitano AM, Lambris JD, Taylor RP.

Clin Immunol. 2016 Oct;171:32-35. doi: 10.1016/j.clim.2016.08.017. Epub 2016 Aug 18.

27.

High-Fat Diet-Induced Complement Activation Mediates Intestinal Inflammation and Neoplasia, Independent of Obesity.

Doerner SK, Reis ES, Leung ES, Ko JS, Heaney JD, Berger NA, Lambris JD, Nadeau JH.

Mol Cancer Res. 2016 Oct;14(10):953-965. Epub 2016 Aug 17.

28.

Systems Analysis of the Complement-Induced Priming Phase of Liver Regeneration.

Min JS, DeAngelis RA, Reis ES, Gupta S, Maurya MR, Evans C, Das A, Burant C, Lambris JD, Subramaniam S.

J Immunol. 2016 Sep 15;197(6):2500-8. doi: 10.4049/jimmunol.1600628. Epub 2016 Aug 10.

29.

From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage.

Mastellos DC, Reis ES, Yancopoulou D, Hajishengallis G, Ricklin D, Lambris JD.

Immunobiology. 2016 Oct;221(10):1046-57. doi: 10.1016/j.imbio.2016.06.013. Epub 2016 Jun 16. Review.

30.

Complement in disease: a defence system turning offensive.

Ricklin D, Reis ES, Lambris JD.

Nat Rev Nephrol. 2016 Jul;12(7):383-401. doi: 10.1038/nrneph.2016.70. Epub 2016 May 23. Review.

31.

Factors Associated With the Development of Chronic Post-Sternotomy Pain: a Case-Control Study.

Costa MA, Trentini CA, Schafranski MD, Pipino O, Gomes RZ, Reis ES.

Braz J Cardiovasc Surg. 2015 Sep-Oct;30(5):552-6. doi: 10.5935/1678-9741.20150059.

32.

Applying complement therapeutics to rare diseases.

Reis ES, Mastellos DC, Yancopoulou D, Risitano AM, Ricklin D, Lambris JD.

Clin Immunol. 2015 Dec;161(2):225-40. doi: 10.1016/j.clim.2015.08.009. Epub 2015 Sep 1. Review.

33.

Rare loss-of-function mutation in complement component C3 provides insight into molecular and pathophysiological determinants of complement activity.

Sfyroera G, Ricklin D, Reis ES, Chen H, Wu EL, Kaznessis YN, Ekdahl KN, Nilsson B, Lambris JD.

J Immunol. 2015 Apr 1;194(7):3305-16. doi: 10.4049/jimmunol.1402781. Epub 2015 Feb 23.

34.

Therapeutic C3 inhibitor Cp40 abrogates complement activation induced by modern hemodialysis filters.

Reis ES, DeAngelis RA, Chen H, Resuello RR, Ricklin D, Lambris JD.

Immunobiology. 2015 Apr;220(4):476-82. doi: 10.1016/j.imbio.2014.10.026. Epub 2014 Nov 3.

35.

Conjugation to albumin-binding molecule tags as a strategy to improve both efficacy and pharmacokinetic properties of the complement inhibitor compstatin.

Huang Y, Reis ES, Knerr PJ, van der Donk WA, Ricklin D, Lambris JD.

ChemMedChem. 2014 Oct;9(10):2223-6. doi: 10.1002/cmdc.201402212. Epub 2014 Jul 23.

36.

The evolution and appearance of C3 duplications in fish originate an exclusive teleost c3 gene form with anti-inflammatory activity.

Forn-Cuní G, Reis ES, Dios S, Posada D, Lambris JD, Figueras A, Novoa B.

PLoS One. 2014 Jun 13;9(6):e99673. doi: 10.1371/journal.pone.0099673. eCollection 2014.

37.

Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria.

Risitano AM, Ricklin D, Huang Y, Reis ES, Chen H, Ricci P, Lin Z, Pascariello C, Raia M, Sica M, Del Vecchio L, Pane F, Lupu F, Notaro R, Resuello RR, DeAngelis RA, Lambris JD.

Blood. 2014 Mar 27;123(13):2094-101. doi: 10.1182/blood-2013-11-536573. Epub 2014 Feb 4. Erratum in: Blood. 2017 Apr 13;129(15):2205.

38.

Clinical accuracy of flapless computer-guided surgery for implant placement in edentulous arches.

Vieira DM, Sotto-Maior BS, Barros CA, Reis ES, Francischone CE.

Int J Oral Maxillofac Implants. 2013 Sep-Oct;28(5):1347-51. doi: 10.11607/jomi.3156.

PMID:
24066327
39.

Complement anaphylatoxin C3a is a potent inducer of embryonic chick retina regeneration.

Haynes T, Luz-Madrigal A, Reis ES, Echeverri Ruiz NP, Grajales-Esquivel E, Tzekou A, Tsonis PA, Lambris JD, Del Rio-Tsonis K.

Nat Commun. 2013;4:2312. doi: 10.1038/ncomms3312.

40.

CMAP: Complement Map Database.

Yang K, Dinasarapu AR, Reis ES, Deangelis RA, Ricklin D, Subramaniam S, Lambris JD.

Bioinformatics. 2013 Jul 15;29(14):1832-3. doi: 10.1093/bioinformatics/btt269. Epub 2013 May 9.

41.

Local complement-targeted intervention in periodontitis: proof-of-concept using a C5a receptor (CD88) antagonist.

Abe T, Hosur KB, Hajishengallis E, Reis ES, Ricklin D, Lambris JD, Hajishengallis G.

J Immunol. 2012 Dec 1;189(11):5442-8. doi: 10.4049/jimmunol.1202339. Epub 2012 Oct 22.

42.

C5a receptor-dependent cell activation by physiological concentrations of desarginated C5a: insights from a novel label-free cellular assay.

Reis ES, Chen H, Sfyroera G, Monk PN, Köhl J, Ricklin D, Lambris JD.

J Immunol. 2012 Nov 15;189(10):4797-805. doi: 10.4049/jimmunol.1200834. Epub 2012 Oct 5.

43.

Targeted complement inhibition as a promising strategy for preventing inflammatory complications in hemodialysis.

DeAngelis RA, Reis ES, Ricklin D, Lambris JD.

Immunobiology. 2012 Nov;217(11):1097-105. doi: 10.1016/j.imbio.2012.07.012. Review.

44.

A sweet spot to control complement-induced inflammation.

Ricklin D, Reis ES, Lambris JD.

Nat Med. 2012 Sep;18(9):1340-1. doi: 10.1038/nm.2916. No abstract available.

PMID:
22961162
45.

Comparative efficiency of two models of CO2 traps in the collection of free-living stages of ixodides.

Guedes E, de Azevedo Prata MC, dos Reis ES, Cançado PH, Leite RC.

Parasitol Res. 2012 Dec;111(6):2325-8. doi: 10.1007/s00436-012-3088-2. Epub 2012 Aug 23.

PMID:
22915273
46.

New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties.

Qu H, Ricklin D, Bai H, Chen H, Reis ES, Maciejewski M, Tzekou A, DeAngelis RA, Resuello RR, Lupu F, Barlow PN, Lambris JD.

Immunobiology. 2013 Apr;218(4):496-505. doi: 10.1016/j.imbio.2012.06.003. Epub 2012 Jun 17.

47.

Sleep and circadian rhythm regulate circulating complement factors and immunoregulatory properties of C5a.

Reis ES, Lange T, Köhl G, Herrmann A, Tschulakow AV, Naujoks J, Born J, Köhl J.

Brain Behav Immun. 2011 Oct;25(7):1416-26. doi: 10.1016/j.bbi.2011.04.011. Epub 2011 Apr 23.

PMID:
21539909
48.

Prevalence and lineage diversity of avian haemosporidians from three distinct cerrado habitats in Brazil.

Belo NO, Pinheiro RT, Reis ES, Ricklefs RE, Braga ÉM.

PLoS One. 2011 Mar 8;6(3):e17654. doi: 10.1371/journal.pone.0017654. Erratum in: PLoS One. 2011;6(4). doi:10.1371/annotation/993592b8-5719-45b1-814e-2052318532e7.

49.

C5a receptor-deficient dendritic cells promote induction of Treg and Th17 cells.

Weaver DJ Jr, Reis ES, Pandey MK, Köhl G, Harris N, Gerard C, Köhl J.

Eur J Immunol. 2010 Mar;40(3):710-21. doi: 10.1002/eji.200939333.

50.

The role of the anaphylatoxins in health and disease.

Klos A, Tenner AJ, Johswich KO, Ager RR, Reis ES, Köhl J.

Mol Immunol. 2009 Sep;46(14):2753-66. doi: 10.1016/j.molimm.2009.04.027. Epub 2009 May 28. Review.

Supplemental Content

Support Center